Sera Prognostics, Inc.
SERA Nasdaq· Services-Medical Laboratories
Last close · Oct 23, 2026
$2.03
KIRA · Stoqly’s AI analyst, in plain words
- Sera Prognostics, Inc. had $0.1M of revenue in fiscal 2025, up 5.2% on the year before. Over five years, revenue changed +26.5% a year on average.
- Its operating margin was −45,066.7%, up 2,511.3 pts: of every 100 in sales, about −45,067 is left after running the business.
- Sera Prognostics, Inc. lost $31.9M in fiscal 2025.
- Free cash flow was −$26.3M in fiscal 2025, −32,529.6% of revenue.
Market cap
$102M
P/E
—
Revenue
$0.1M
Net income
−$31.9M
Free cash flow
−$26.3M
Operating margin
−45,066.7%
Sera Prognostics, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+5.2%
Yes. Sales grew 5.2% last year.
Does it make a profit?
−39,417.3%
No. It lost money last year.
Does profit turn into cash?
−32,529.6%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Sera Prognostics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 18, 2026
- Legal name
- SERA PROGNOSTICS, INC.
- CIK
- 0001534969
Sera Prognostics, Inc. · SERA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.1M | $0.3M | $0.3M | $0.1M | $0.1M |
| Revenue growth | 228.0% | 226.8% | 14.2% | −74.8% | 5.2% |
| Gross margin | — | — | 31.4% | −6.5% | −102.5% |
| Operating margin | −43,164.6% | −17,034.3% | −13,013.4% | −47,577.9% | −45,066.7% |
| Net income | −$35.0M | −$44.2M | −$36.2M | −$32.9M | −$31.9M |
| Net margin | −42,693.9% | −16,487.3% | −11,843.8% | −42,724.7% | −39,417.3% |
| Diluted EPS | −$2.33 | −$1.43 | −$1.16 | −$0.99 | −$0.67 |
| Cash | |||||
| Cash from operations | −$31.6M | −$34.6M | −$27.2M | −$14.2M | −$25.6M |
| Capital expenditure | $1.3M | $0.8M | $0.1M | $0.1M | $0.7M |
| Free cash flow | −$32.9M | −$35.4M | −$27.3M | −$14.2M | −$26.3M |
| FCF margin | −40,170.7% | −13,209.3% | −8,926.8% | −18,500.0% | −32,529.6% |
| Share count change | 864.4% | 106.2% | 0.8% | 6.3% | 43.7% |
| Debt and strength | |||||
| Cash and short-term investments | $105M | $82.7M | $49.1M | $46.2M | $39.2M |
| Shareholders' equity | $139M | $98.9M | $70.2M | $47.8M | $75.4M |
| Current ratio | 13.1x | 5.8x | 2.5x | 1.9x | 1.7x |
| Interest coverage | — | — | −724.0x | −1,308.4x | −4,056.0x |
| Returns and quality | |||||
| Return on equity | −538.8% | −37.2% | −42.9% | −55.8% | −51.8% |
| Return on tangible equity | −25.3% | −44.7% | −51.7% | −70.3% | −42.9% |
| Piotroski F-score | 3 | 2 | 3 | 1 | 2 |
| Altman Z'' | 16.4 | 1.6 | −5.8 | −11.9 | −8.3 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.7M
10 insiders
Of sales under plans
7%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Sera Prognostics, Inc. · SERA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.03 a share, the company is worth $102M.
Source: SEC EDGAR XBRL filings (CIK 0001534969). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.